1 / 37

GASTRIC CANCER 2007

GASTRIC CANCER 2007. GASTRIC CANCER 2007. Epidemiologic Trends • worldwide decline in age-adjusted incidence now parallels pattern previously observed in United States • disease now appearing anatomically in a more proximal pattern. GASTRIC CANCER 2007. International Mortality Trends.

kalyca
Download Presentation

GASTRIC CANCER 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GASTRIC CANCER 2007

  2. GASTRIC CANCER 2007 Epidemiologic Trends • worldwide decline in age-adjusted incidence now parallels pattern previously observed in United States • disease now appearing anatomically in a more proximal pattern

  3. GASTRIC CANCER 2007 International Mortality Trends

  4. GASTRIC CANCER 2007 Question • is there a “best” treatment for metastatic disease?

  5. GASTRIC CANCER 2007 Active Single Agents fluorouracil anthracyclines (doxorubicin, epirubicin) cisplatin irinotecan taxanes (docetaxel, paclitaxel)

  6. GASTRIC CANCER 2007

  7. GASTRIC CANCER 2007 Chemotherapy is Superior to Best Supportive Care Wagner, et. al. JCO 2006;24:2903

  8. GASTRIC CANCER 2007 Advanced Disease Is any one of these various drug combinations superior to the others?

  9. GASTRIC CANCER 2007

  10. GASTRIC CANCER 2007 Combination vs Single-Agent Chemotherapy Wagner, et. al. JCO 2006;24:2903

  11. GASTRIC CANCER 2007

  12. GASTRIC CANCER 2007 Treatment of Metastatic Disease • many active combinations • none clearly superior • ECF perhaps best balance between efficacy and tolerability

  13. GASTRIC CANCER 2007 Recent Interest in Oral Fluoropyrimidines • oral preparation of 5-FU was discarded because of erratic absorption thought due to variable concentrations of DPD in the GI mucosa • three novel forms of oral 5-FU are now available - capecitabine (Xeloda) - UFT (uracil and tegafur) - S-1

  14. GASTRIC CANCER 2007 Capecitabine from: Ajani. Cancer 2006;107:221

  15. GASTRIC CANCER 2007 Capecitabine • phase II data as single agent or when combined with cisplatin similar to results with 5-FU • phase III comparisons reported at ASCO in 2006 showed identical outcomes in treating metastatic disease for: - ECF vs. ECX (Cunningham, et. al.) - FP vs. XP (Kang et. al.)

  16. GASTRIC CANCER 2007 UFT • uracil binds to DPD, facilitating the absorption of tegafur, a prodrug of 5-FU • has been utilized in metastatic gastric cancer as a single agent or in combination with mitomycin or cisplatin • has been examined in phase III trials in Japan in metastatic and adjuvant settings

  17. GASTRIC CANCER 2007

  18. GASTRIC CANCER 2007

  19. GASTRIC CANCER 2007 S-1 • oral fluoropyrimidine consisting of tegafur, CDHP, and OXO in a 1:0.4:1 molar ratio - tegafur is converted to 5-FU - CDHP (chloro-2.4-dihydroxypyridine) inhibits DPD, preventing 5-FU degradation - OXO (potassium oxonate) protects against drug induced diarrhea caused by phosphorylation of 5- FU by inhibiting the responsible enzyme – OPRT (oronate phosphoribosyl transferase) • phase II trials in Japanese patients with advanced gastric cancer were encouraging

  20. GASTRIC CANCER 2007

  21. GASTRIC CANCER 2007 JCOG 9912 (Boku, et. al.) Study Design • OS represented the primary endpoint • dual comparisons to 5-FU - superiority of irinotecan/cisplatin - non-inferiority of S-1 • three stratifications (PS, de novo vs. recurrence, center) • 704 randomized patients well balanced - only 3 had received prior adjuvant chemotherapy - equal proportion intestinal/diffuse histologies

  22. GASTRIC CANCER 2007

  23. GASTRIC CANCER 2007 JCOG 9912 (Boku, et. al.) Observations • neither the 5-FU nor the irinotecan/cisplatin regimens as given in this trial are commonly used in the US or Europe • toxicity led to the withdrawal of 32.1% of the irinotecan/cisplatin cohort compared to a 9.4% and 7.7% withdrawal rate for patients randomized to S-1 or 5-FU respectively • in retrospect, a prospective stratification for “measurable vs. non-measurable” disease would have been useful

  24. GASTRIC CANCER 2007 JCOG 9912 (Boku, et. al.) Conclusions • results with S-1 are impressive (11.4 month median survival) • however – premature to annoint S-1 as “the standard chemotherapy for unresectable or recurrent gastric cancer”

  25. GASTRIC CANCER 2007

  26. GASTRIC CANCER 2007 SPIRITS Trial (Narahara, et. al.) Study Design • OS represented the primary endpoint • three stratifications (PS, de novo vs. recurrent, center) • 298 evaluable patients - S-1/cisplatin cohort contained a greater proportion of patients with diffuse histology (p=0.079) and peritoneal carcinomatosis (p=0.056)

  27. GASTRIC CANCER 2007

  28. GASTRIC CANCER 2007 SPIRITS Trial (Narahara, et. al.) Conclusions • S-1/cisplatin regimen: - was well tolerated - was superior to single agent S-1, even though it was given to patients with more ominous prognostic features - merits further study

  29. GASTRIC CANCER 2007

  30. GASTRIC CANCER 2007

  31. GASTRIC CANCER 2007

  32. GASTRIC CANCER 2007 • would S-1 be a superior form of fluoropyrimidine therapy if used outside of Japan?

  33. GASTRIC CANCER 2007 American Experience with S-1 • Asian and white individuals have different rates of activation of tegafur to 5-FU - such activation is dependent on an hepatic cytochrome P450 enzyme (CYP2A6) - different polymorphisms of the CYP2A6 gene exist among Asians and whites

  34. GASTRIC CANCER 2007 American Experience with S-1 • a phase I study in 16 American patients suggested a “25mg/m2 bid” dose being optimal for “Westerners” rather than the “40mg/m2 bid” dose utilized in Japan (Ajani, et. al. JCO 2005;23:6957)

  35. GASTRIC CANCER 2007 American Experience with S-1 • multicenter phase II trial involving 72 American patients (74% white, 15% black or Latino) previously untreated for metastatic disease S-1 (25mg/m2 bid d 1-21) + cisplatin (75mg/m2 d 1) q 28 days • report: 55% response rate 5.6 month median PFS 10.4 month median OS Ajani, et. al. JCO 2006;24:663 Lenz, et. al. Cancer 2007;109:33

  36. GASTRIC CANCER 2007 First-Line Advanced Gastric Cancer Study (FLAGS) • ongoing worldwide phase III trial involving >1000 patients • comparison of: 5-FU/cisplatin S-1/cisplatin • hopefully will be addressing cost and quality of life as well as efficacy

  37. GASTRIC CANCER Stay Tuned!

More Related